ABSTRACT The effect of adding slow release nifedipine to oral theophylline has been studied in eight patients with stable but symptomatic asthma, a double blind placebo controlled crossover protocol being used. No change in asthma control occurred during the nifedipine treatment period as assessed by serial peak flow measurements and symptom scores. Serum theophylline concentrations were significantly lower after nifedipine than after placebo (6-8 v 9-7 g/ml) and in three patients were well below the therapeutic range ( < 4 jg/ml).
extent.' They may, however, have a beneficial effect when combined with other treatment for asthma. Nifedipine potentiates the bronchodilator effect of inhaled salbutamol2 and intravenous terbutaline3 in acute studies in asthmatic subjects and it enhances the airways smooth muscle relaxation induced by theophylline4 in isolated guinea pig trachea. We have studied asthma control in a group of patients with stable but symptomatic asthma when nifedipine was added for two weeks to their usual asthma treatment, which included theophylline.
Several drugs are known to influence theophylline pharmacokinetics' and these are important clinically in view of the narrow therapeutic range of theophylline. Nifedipine is widely used to treat angina and hypertension in asthmatic patients, in whom / adrenoceptor antagonists are contraindicated. We have therefore evaluated the effect of nifedipine on serum theophylline concentrations.
Methods
We recruited 10 patients (six male, four female), with a mean age of 56 (range 49-70) years and with stable but symptomatic asthma. All Once satisfactory serum theophylline concentrations had been achieved, patients were asked to record symptoms and the best achievable peak expiratory flow (PEF) each day at 8am, 12 noon, 6pm, and 10pm, before they used their bronchodilator inhaler. Symptoms included perceived severity of asthma, degree of dyspnoea, cough, and disturbance of sleep due to asthma, each being assessed on a 0-10 scale (that is, no symptoms = 0, very severe symptoms = 10). No change was made to their usual treatment during the first week, which served as a "practice" period. At the end of the week any problems with recordings were resolved and blood was taken for measurement of serum theophylline concentrations. These were found to be stable and within the therapeutic range in all 10 patients. Subjects were started on slow release nifedipine 20 mg twice daily or an identical placebo tablet twice daily in addition to their usual treatment in a randomised double blind fashion. Measurements of PEF and symptom recordings were continued for a further two weeks, after which further blood was taken for serum theophylline assay. Subjects who had received nifedipine were changed to placebo and vice versa. Recordings were continued for another two weeks, at the end of which a final serum theophylline measurement was made.
Compliance with treatment was checked by tablet counts at the end of each of the two treatment periods.
Statistical comparisons were made by means of Student's t test.
Results
Two men (one from each limb of the study) had to withdraw because of troublesome headache, which developed within 24 hours of starting nifedipine. The remaining eight subjects tolerated the treatment without side effects.
There was no significant difference in mean PEF measurements or combined symptom scores between the placebo and the nifedipine period (table). The combined symptom score represents the sum of the The mean (SEM) serum theophylline concentration was similar after two weeks' placebo to the concentration immediately before entry to the randomised part of the study (97 (05) pg/ml after placebo compared with 9 6 (0 9) pg/ml after one week's practice). After nifedipine the mean theophylline concentration was significantly lower (6 8 (1 0),g/ml) than after either the placebo or the practice period (p < 0 02 for both comparisons; figure) . In three patients serum theophylline concentrations after nifedipine were 4,ug/ml or less, representing falls of 64%, 56%, and 50% from the levels seen after placebo.
Mean peak expiratoryflow! and combined symptom scores (wilh standard errors in parentheses) during placebo and nifedipine treatment periods in eight asthmatic subjects The fall in theophylline concentrations during nifedipine administration may be explained by the results of a study in normal volunteers by Jackson and colleagues.9 They found that serum theophylline concentrations after an infusion of lysine theophylline were significantly lower in the presence of nifedipine during steady state chronic oral dosing owing to an increase in the mean volume of distribution of theophylline. Alternatively, nifedipine might alter theophylline absorption, although this would not account for the results with intravenous theophylline,9 or nifedipine might increase theophylline clearance by increasing liver blood flow. The latter is unlikely since, although nifedipine does increase liver blood flow,'0 theophylline is subject to low hepatic extraction with a small first pass loss. Its clearance is more dependent on the activity of liver enzymes than on changes in liver blood flow. " We suggest that, when nifedipine is used to treat angina or hypertension in patients with brittle asthma Smith, Wiggins, Stableforth, Skinner, Kendall who are taking oral theophylline, serum theophylline concentrations should be monitored during the first few weeks so that appropriate dose adjustments can be made.
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